| Abstrakt: |
Clinical background and environmental factors in colombian patients with multiple sclerosis B QUIÑONES-BAUTISTA, Jairo Alonso b | PINILLA-MONSALVE, Gabriel David | PUGLIESE-RENGIFO, Isabella | VALDERRAMA-CHAPARRO, Jaime Andrés I Fundación Valle Del Lili i B Introduction: b Multiple sclerosis (MS) is an autoimmune disorder related to several environmental factors; unfortunately, there is a significant lack of data for inhabitants of the tropical circles. 0087 Safety of the COVID-19 vaccines in patients with multiple sclerosis from latin america B ALONSO, Ricardo b (1) | CHERTCOFF, Anibal Sebastian(2) | LEGUIZAMON, Felisa(3) | GALLEGUILLOS, Lorna(4) | EIZAGUIRRE, María Bárbara(1) | GIACHELLO, Susana(5) | BAUER, Johana(6) | SILVA, Berenice Anabel(1) I Centro Universitario De Esclerosis Múltiple, Hospital Ramos Mejía (1); Hospital Británico De Buenos Aires (2); Hospital Alvarez (3); Clínica Alemana (4); Asociacion Lucha Contra La Esclerosis Multiple- Alcem (5); Esclerosis Múltiple Argentina (6) i B Introduction: b To date, there are no data available on the safety of COVID-19 vaccines in Latin American patients with Multiple Sclerosis(MS). 0057 Natalizumab extended dose experience in multiple sclerosis patients: Data from daily clinical... B ORTIZ SALAS, Paola b | ZULUAGA RODAS, María Isabel | OROZCO GONZÁLEZ, Catalina | VAGNER, Basilio | GORTARI, José Ignacio | MIRANDA, Jahir | CAMACHO BARBOSA, Jhyld Carolaind | DUQUE ZAPATA, Natalia I Medicarte S.A.S i B Introduction: b Natalizumab (NTZ) is effective in treating relapsing forms of multiple sclerosis (MS), but; over 2 years of treatment, previous use of immunosuppressants and antibodies against JC virus (VJC), are predictive factors of progressive multifocal leukoencephalopathy (PML) B Objectives: b To compare clinical characteristics of patients with standard dose interval (SDI) vs extended dose (EDI) (>4 weeks) of NTZ. [Extracted from the article] |
